×
About 59,306 results

ALLMedicine™ Psoriasis Center

Research & Reviews  25,413 results

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation admin...
https://doi.org/10.1080/09546634.2021.1914812
The Journal of Dermatological Treatment; Blauvelt A, Gordon KB et. al.

May 5th, 2021 - Risankizumab is approved for treatment of moderate to severe plaque psoriasis. Availability of a patient-controlled single self-injection of risankizumab may improve adherence and long-term management of psoriasis. To investigate efficacy, safety,...

Rupioid Psoriasis.
https://doi.org/10.1001/jamadermatol.2021.0451
JAMA Dermatology; Ip KH, Cheng HS et. al.

May 5th, 2021 - Rupioid Psoriasis.|2021|Ip KH,Cheng HS,Oliver FG,|

Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach.
https://doi.org/10.1111/joim.13282
Journal of Internal Medicine; Hedin CRH, Sonkoly E et. al.

May 4th, 2021 - Psoriasis and inflammatory bowel disease (IBD) are immune-mediated diseases occurring in barrier organs whose main task is to protect the organism from attack. These disorders are highly prevalent especially in northern Europe where psoriasis has ...

Identification of a Long Noncoding RNA TRAF3IP2-AS1 as Key Regulator of IL-17 Signaling...
https://doi.org/10.4049/jimmunol.2001223
Journal of Immunology (Baltimore, Md. : 1950); He R, Wu S et. al.

May 4th, 2021 - IL-17A plays an essential role in the pathogenesis of many autoimmune diseases, including psoriasis and multiple sclerosis. Act1 is a critical adaptor in the IL-17A signaling pathway. In this study, we report that an anti-sense long noncoding RNA,...

Systematic literature review of long-term efficacy data for topical psoriasis treatments.
https://doi.org/10.1080/09546634.2021.1925211
The Journal of Dermatological Treatment; Bark C, Brown C et. al.

May 4th, 2021 - To identify long-term efficacy evidence that supports use of topical therapies as regular maintenance therapy in the prevention of psoriasis relapse. A systematic literature review identified clinical trials and observational studies that reported...

see more →

Guidelines  209 results

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specifi...
https://doi.org/10.1111/jdv.16926
Journal of the European Academy of Dermatology and Venere... Nast A, Smith C et. al.

Feb 6th, 2021 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clini...

National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788316
Journal of the American Academy of Dermatology; Gelfand JM, Armstrong AW et. al.

Jan 10th, 2021 - To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic. The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical ca...

Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway.
https://doi.org/10.1159/000512930
Dermatology (Basel, Switzerland); Maul JT, Anzengruber F et. al.

Jan 6th, 2021 - Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choic...

Portuguese recommendations for the treatment of psoriasis with biologic therapy.
https://doi.org/10.1684/ejd.2020.3945
European Journal of Dermatology : EJD; Torres T, Tavares Bello R et. al.

Dec 10th, 2020 - Psoriasis is a highly prevalent chronic, inflammatory multisystem disease with a considerable impact on patients' quality of life and the healthcare system. This report presents the recommendations developed by the Portuguese Psoriasis Group of th...

Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function
https://onlinelibrary.wiley.com/doi/10.1002/acr2.11196
ACR Open Rheumatology; Liphardt AM

Nov 24th, 2020 - The objective of this study was to compare the impact of psoriatic disease (psoriatic arthritis [PsA] and psoriasis) and rheumatoid arthritis (RA) on objective and subjective parameters of hand function.

see more →

Drugs  1,355 results see all →

Clinicaltrials.gov  28,345 results

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation admin...
https://doi.org/10.1080/09546634.2021.1914812
The Journal of Dermatological Treatment; Blauvelt A, Gordon KB et. al.

May 5th, 2021 - Risankizumab is approved for treatment of moderate to severe plaque psoriasis. Availability of a patient-controlled single self-injection of risankizumab may improve adherence and long-term management of psoriasis. To investigate efficacy, safety,...

Rupioid Psoriasis.
https://doi.org/10.1001/jamadermatol.2021.0451
JAMA Dermatology; Ip KH, Cheng HS et. al.

May 5th, 2021 - Rupioid Psoriasis.|2021|Ip KH,Cheng HS,Oliver FG,|

Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach.
https://doi.org/10.1111/joim.13282
Journal of Internal Medicine; Hedin CRH, Sonkoly E et. al.

May 4th, 2021 - Psoriasis and inflammatory bowel disease (IBD) are immune-mediated diseases occurring in barrier organs whose main task is to protect the organism from attack. These disorders are highly prevalent especially in northern Europe where psoriasis has ...

Identification of a Long Noncoding RNA TRAF3IP2-AS1 as Key Regulator of IL-17 Signaling...
https://doi.org/10.4049/jimmunol.2001223
Journal of Immunology (Baltimore, Md. : 1950); He R, Wu S et. al.

May 4th, 2021 - IL-17A plays an essential role in the pathogenesis of many autoimmune diseases, including psoriasis and multiple sclerosis. Act1 is a critical adaptor in the IL-17A signaling pathway. In this study, we report that an anti-sense long noncoding RNA,...

Systematic literature review of long-term efficacy data for topical psoriasis treatments.
https://doi.org/10.1080/09546634.2021.1925211
The Journal of Dermatological Treatment; Bark C, Brown C et. al.

May 4th, 2021 - To identify long-term efficacy evidence that supports use of topical therapies as regular maintenance therapy in the prevention of psoriasis relapse. A systematic literature review identified clinical trials and observational studies that reported...

see more →

News  3,765 results

Brodalumab Shows Promise in Axial Spondyloarthritis
https://www.medscape.com/viewarticle/950264

May 2nd, 2021 - NEW YORK (Reuters Health) - Brodalumab may be a potential therapeutic option for patients with axial spondyloarthritis (axSpA), according to interim results of a phase-3 study. Brodalumab, which selectively inhibits interleukin-17 receptor A (IL-1...

Two Studies Add to Knowledge Base of Biosimilar Use in Psoriasis, HS
https://www.medscape.com/viewarticle/950197

Apr 28th, 2021 - A cohort study of psoriasis patients in Denmark found that a nonmedical switch from brand name adalimumab to adalimumab biosimilars was not associated with drug retention at 1 year. And another study, a small, single-center retrospective study of ...

TNF Inhibitors Linked to Threefold Increased Risk of Psoriasis in JIA Patients
https://www.medscape.com/viewarticle/950220

Apr 28th, 2021 - Children with juvenile idiopathic arthritis (JIA) have nearly triple the risk of developing psoriasis after they begin therapy with tumor necrosis factor (TNF) inhibitors, according to preliminary research shared at the annual meeting of the Child...

Psoriasis Associated With an Increased Risk for COVID-19 in Real-World Study
https://www.medscape.com/viewarticle/950098

Apr 27th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. People with psoriasis have a higher risk of infection with COVID-19 than the general population, but some systemic treatments appear to lower risk...

Debate: Should Biologics Be Used for Milder Cases of Psoriasis?
https://www.medscape.com/viewarticle/949919

Apr 24th, 2021 - The remarkable efficacy of biologics for moderate-to-severe psoriasis has led some to ask if biologics should be used for milder cases. The issue was tackled in a debate at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 2...

see more →

Patient Education  219 results see all →